Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In Lung Cancer
Lung Cancer for July/August 2016
PD-1 Inhibitor–Related Pneumonitis Evaluated, JAMA Oncol; ePub 2016 Aug 18; Nishino, et al
Therapies Focusing on KRAS-Mutated Cancers Evaluated, J Clin Oncol; ePub 2016 Aug 1; Papadimitrakopoulou, et al
Use This Assessment When Screening for Lung Cancer, Cancer Epidemiol Biomarkers Prev; ePub 2016 Jul 6; Schwartz, et al
New Test Approved for Non-Small Cell Lung Cancer, FDA news release; 2016 Jun 1
Lung Cancer for May/June 2016
Leisure-Time Physical Activity and Risk of Cancer , JAMA Intern Med; ePub 2016 May 16; Moore, et al
Lung Cancer for March/April 2016
Rapid Plasma Genotyping in Advanced Lung Cancer, JAMA Oncol; ePub 2016 Apr 7; Sacher, et al
Brain Metastases from NSCLC, Lung Cancer; ePub 2016 Apr 6; Hsu, et al
Urinary Metabolites as Lung Cancer Screening Tools, Cancer Epidemiol Biomarkers Prev; ePub 2016 Mar 24; Haznadar, et al
Incidence and Mortality in Lung Cancer, Lancet Oncol; ePub 2016 Mar 18; Patz, Greco, et al
FDA Approves Additional Xalkori Indication, Pfizer news release; 2016 Mar 11
Lung Cancer for January/February 2016
Tumor Lymphocytic Infiltration in NSCLC, Assessing its prognostic value
Mutant RB1 vs Wild Type RB1 in SCLC, Which tumor type responds better to chemotherapy?
Dacomitinib and Erlotinib in NSCLC, Comparing survival and safety
MET Exon 14 Mutations in NSCLC, Are they a unique subtype?
Familial Risk in Cancers of Unknown Primary, What are the risks for first- and second-degree relatives?
Lung Cancer for November/December 2015
FDA Approves Alecensa, Indicated for ALK+, metastatic NSCLC
FDA Approves Vistogard, Indicated as chemotherapy antidote
High Dose Radiation Therapy in NSCLC, Comparing quality of life after 74-Gy or 60-Gy dosing
Medicare Eligibility for Lung Cancer Screening, Do screening rates align with risk for Blacks, Hispanics?
FDA Approves Tagrisso, Oral medication for non-small cell lung cancer